Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1Breast 1

Conditions

Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Neoplasms 1Head and Neck Neoplasms 1Breast Neoplasms 1

Interventions

Gemcitabine 83Cisplatin 59pembrolizumab 28Paclitaxel 21Nivolumab 21Carboplatin 21Cystectomy 20Docetaxel 18durvalumab 17atezolizumab 17Magnetic Resonance Spectroscopy 16Specimen Handling 15Radiotherapy 14avelumab 13Mitomycin 13Sunitinib 12Doxorubicin 12Methotrexate 11Fluorouracil 11Vinblastine 10Filgrastim 7BCG Vaccine 7Sorafenib 6Ipilimumab 6Immunoglobulin G 6Disulfides 6Biopsy 6enfortumab vedotin 5cabozantinib 5Trastuzumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Urinary Bladder Neoplasms × Tetrahydrouridine × Clear all
NCT00978250 2019-12-27

A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
95 enrolled 15 charts
BreastGenitourinaryHead & NeckThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡